Next 10 |
home / stock / dyn / dyn articles
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) an...
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of Aehr Test Systems (NASDAQ: AEHR) fell sharply duri...
Cantor Fitzgerald has initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA), noting the company has the complete package, inclu...
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adv...
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE: COO) rose sharply du...
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the P...
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advan...
News, Short Squeeze, Breakout and More Instantly...
2024-04-20 23:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an induceme...
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...